Sun Pharmaceutical (SUNPHARMA) — concall transcript

📢 Key Event
Sun Pharma reported FY24 revenue growth of 10.4%, EBITDA margin of 26.9%, and proposed INR5 final dividend, taking total to INR13.5 per share.

🔄 What Changed
Adjusted net profit grew 16.5% YoY to INR95,764 million; gross margin improved by over 200 bps YoY; R&D spend increased by over 200 bps; Nigeria forex loss recorded as exceptional item.

🔮 What's Next
FY25 targets high single-digit top-line growth with R&D investment planned at 8-10% of sales; Deuruxo launch expected in July 2024 with pre-launch costs impacting H2; Phase III trials planned for MM-II after Phase II failure.

💡 Investor Takeaway
Sun Pharma delivered strong margin expansion and profit growth despite currency headwinds, with clear FY25 growth targets and R&D focus on specialty products, though regulatory and pricing uncertainties remain.

Sun Pharmaceutical reported FY24 revenue growth of 10.4% and EBITDA margin of 26.9%, with adjusted net profit up 16.5% to INR95,764 million. Q4 saw 10.1% YoY sales growth to INR118,133 million and 25.3% EBITDA margin. The company proposed a final dividend of INR5 per share, taking FY24 total to INR13.5. FY25 guidance targets high single-digit top-line growth and R&D investment of 8-10% of sales. Management highlighted strong growth in U.S. generics (10.9% YoY), specialty business (19.3% YoY), and emerging markets (17% constant currency growth), driven by products like ILUMYA and Winlevi. Gross margin improved by over 200 bps YoY due to product mix and geography, while R&D spend was raised by over 200 bps. FDA audit concerns at Mohali and Dadra sites are being addressed with corrective actions underway. Deuruxo launch is expected in July 2024 with pre-launch costs impacting H2, and Phase III trials are planned for MM-II despite Phase II failure. Nigeria forex depreciation caused a P&L loss, and pricing environment remains unchanged with no major new launch impacts anticipated in 1-2 years.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹4,63,791.45 Cr P/E: 38.4 ROE: 14.6% ROCE: 18.7% Div Yield: 0.83%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"What is the expected revenue impact of Deuruxo launch in FY25?" "How will Nigeria forex volatility affect future quarterly results?" "What is the timeline for ILUMYA's psoriatic arthritis indication launch?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 31 March 2024

BEL Bharat Electronics Ltd concall transcript M&M Mahindra & Mahindra Ltd concall transcript SBIN State Bank of India concall transcript ULTRACEMCO UltraTech Cement Ltd concall transcript TITAN Titan Company Ltd concall transcript ETERNAL Eternal Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd